NextCell Pharma
NextCell signs an agreement for a new tissue product
The private stem cell bank Cellaviva, which is owned by NextCell, has been licensed from the Swedish Health Authority (IVO) to operate a tissue facility in Sweden since 2014, which is a regulatory requirement to handle this type of product. Logistics, distribution, and warehousing are core business activities for Cellaviva, and Tience is a welcome source of income that generates profit from the start, regardless of the strength of sales. The great interest in this type of product could soon provide Cellaviva with significant revenue in variable remuneration.
"The Swedish market is very important to Linio and we have a waiting list of clinics that hope to gain access to Tience already this year. NextCell and Cellaviva were an obvious choice for us as partners, with almost 10 years of experience in operating tissue facilities," says Karita Reijonsaari, CEO at Linio Biotech.
More information about Linio Biotech and the product Tience can be found at https://www.linio-biotech.com/
Datum | 2023-10-10, kl 13:00 |
Källa | Cision |
![](https://static.allaaktier.se/ads/hand-waving-2.png)